Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 245 Carcinoma, Non-Small-Cell Lung 225 Prostatic Neoplasms 113 Neoplasms 104 Multiple Myeloma 90 Neoplasm Metastasis 75 Colorectal Neoplasms 73 Parkinson Disease 4, Autosomal Dominant Lewy Body 69 Lung Neoplasms 66 Ovarian Neoplasms 61 Leukemia, Myeloid, Acute 50 Carcinoma, Hepatocellular 47 Melanoma 46 Leukemia, Lymphocytic, Chronic, B-Cell 44 Carcinoma, Renal Cell 43 Urinary Bladder Neoplasms 41 Stomach Neoplasms 41 Squamous Cell Carcinoma of Head and Neck 41 Triple Negative Breast Neoplasms 40 Recurrence 40 Brain Neoplasms 40 Myasthenia Gravis 37 Small Cell Lung Carcinoma 35 Lymphoma, Follicular 35 Nasopharyngeal Carcinoma 34 Head and Neck Neoplasms 33 Pancreatic Neoplasms 32 Rectal Neoplasms 30 Lymphoma, Large B-Cell, Diffuse 30 Colonic Neoplasms 29

Interventions

ribociclib 1 palbociclib 1 abemaciclib 1 Letrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × HR+/HER2- Breast Cancer × 1 year × Clear all

NCT07492641 2026-06-03

KANDELA-302

BeOne Medicines

Phase 3 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡